Shopping Cart

Your shopping cart is currently empty

Ginsenoside Ro

Name: Ginsenoside Ro
Brand: TargetMol
SKU: T3915
Price: 40 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T3915Cas No. 34367-04-9

Alias Polysciasaponin P3, Chikusetsusaponin V, Chikusetsusaponin 5

Ginsenoside Ro (Chikusetsusaponin V) can reduce TXA2 production, weakly reduce COX-1 and TXAS activities, and has antiplatelet effects as a Ca2+ antagonist with an IC50 of 155 μM.

Ginsenoside Ro

Copy Product Info

😃Good

Purity: 99.66%

Catalog No. T3915Alias Polysciasaponin P3, Chikusetsusaponin V, Chikusetsusaponin 5Cas No. 34367-04-9

Ginsenoside Ro (Chikusetsusaponin V) can reduce TXA2 production, weakly reduce COX-1 and TXAS activities, and has antiplatelet effects as a Ca2+ antagonist with an IC50 of 155 μM.

Pack Size	Price	USA Warehouse	Global Warehouse
5 mg	$40	In Stock	In Stock
10 mg	$73	In Stock	In Stock
25 mg	$163	In Stock	In Stock
50 mg	$278	In Stock	In Stock
100 mg	$393	-	In Stock
200 mg	$539	-	In Stock
1 mL x 10 mM (in DMSO)	$77	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.66%

Color:White

Resource Download

COA HPLC HNMR

Product Introduction

Ginsenoside Ro AI Summary

Ginsenoside Ro exhibits multiple bioactivities, including inhibiting hyaluronidase, reducing human amyloid beta (1-40) aggregation, and providing hepatoprotective effects. Specifically, it demonstrated an inhibitory effect on hyaluronidase with an IC50 value of 34000.0 nM, using a colorimetric assay involving hyaluronic acid as a substrate. Additionally, it showed 20.1% activity in reducing amyloid beta aggregation at 25 uM over 24 hours, measured via a Th-T fluorescence assay. Furthermore, Ginsenoside Ro exhibited hepatoprotective activity by decreasing the GPT level by 42.0% at a concentration of 1.0 ug/mL in rat hepatocytes exposed to CCl4/GaIN-induced cytotoxicity..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Ginsenoside Ro (Chikusetsusaponin V) can reduce TXA2 production, weakly reduce COX-1 and TXAS activities, and has antiplatelet effects as a Ca2+ antagonist with an IC50 of 155 μM.
Targets&IC50	Ca2+ antagonistic:155 μM
Synonyms	Polysciasaponin P3, Chikusetsusaponin V, Chikusetsusaponin 5

Chemical Properties

Molecular Weight	957.11
Formula	C₄₈H₇₆O₁₉
Cas No.	34367-04-9
Smiles	CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O[C@@H]6O[C@@H]([C@@H](O)[C@H](O)[C@H]6O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
Relative Density.	1.44g/cm3

Storage & Solubility Information

Storage

In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 245 mg/mL (255.98 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (2.09 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	1.0448 mL	5.2241 mL	10.4481 mL	52.2406 mL
5 mM	0.2090 mL	1.0448 mL	2.0896 mL	10.4481 mL
10 mM	0.1045 mL	0.5224 mL	1.0448 mL	5.2241 mL
20 mM	0.0522 mL	0.2612 mL	0.5224 mL	2.6120 mL
50 mM	0.0209 mL	0.1045 mL	0.2090 mL	1.0448 mL
100 mM	0.0104 mL	0.0522 mL	0.1045 mL	0.5224 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc